Merck
CN

Management of epidermolysis bullosa acquisita.

Dermatologic clinics (2011-09-20)
Lizbeth R A Intong, Dédée F Murrell
摘要

Epidermolysis bullosa acquisita is a rare and debilitating autoimmune mucocutaneous blistering disease caused by autoantibodies directed against type VII collagen or anchoring fibrils in the subepidermal basement membrane zone. Treatment is quite challenging because this disease can be recalcitrant to multiple modalities. This article discusses the current management of this disease.

材料
货号
品牌
产品描述

Supelco
磺胺吡啶熔点标准品, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
磺胺吡啶, ≥99.0%
Supelco
磺胺吡啶, VETRANAL®, analytical standard